2. Metabolic Enzyme/Protease
  3. Endogenous Metabolite
  4. 3-Hydroxyanthranilic acid

3-Hydroxyanthranilic acid is a tryptophan metabolite in the kynurenine pathway.3-hydroxyanthranilic acid has anti-inflammatory, neuroprotective, and lipid-lowering effects. 3-hydroxyanthranilic acid can be used for researches of cardiovascular diseases, tumors, and metabolic diseases.

For research use only. We do not sell to patients.

3-Hydroxyanthranilic acid Chemical Structure

3-Hydroxyanthranilic acid Chemical Structure

CAS No. : 548-93-6

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of 3-Hydroxyanthranilic acid:

3-Hydroxyanthranilic acid Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE 3-Hydroxyanthranilic acid

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

3-Hydroxyanthranilic acid is a tryptophan metabolite in the kynurenine pathway.3-hydroxyanthranilic acid has anti-inflammatory, neuroprotective, and lipid-lowering effects. 3-hydroxyanthranilic acid can be used for researches of cardiovascular diseases, tumors, and metabolic diseases[1][2][3][4][5][6][7][8].

IC50 & Target

Human Endogenous Metabolite

 

In Vitro

3-hydroxyanthranilic acid (12.5-100 μM, 24-72 h) selectively induces activated T cell death via intracellular GSH depletion[2].
3-hydroxyanthranilic acid (100-200 μM, 6 h) reduces ability of BMDCs stimulated with LPS to produce cytokines (IL-12, IL-6, and TNF-α) and DC maturation[3].
3-hydroxyanthranilic acid (0-100 μM, 1-72 h) plays anti-inflammatory and neuroprotective roles via Hemeoxygenase-1 in primary human fetal central nervous system cultures[4].
3-hydroxyanthranilic acid (1-50 μM, 6 h) inhibits monocyte chemoattractant protein-1 secretion and vascular cell adhesion molecule-1 expression via heme oxygenase-1 induction in human umbilical vein endothelial cells[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3-Hydroxyanthranilic acid Related Antibodies
In Vivo

3-hydroxyanthranilic acid (40 μg/each mouse, injected intracerebrally into the forebrains) can induce HO-1 in 8-week-old C57BL6 mice[4].
3-hydroxyanthranilic acid (200 mg/kg, i.p., three times a week, 8 weeks) lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice[5].
3-hydroxyanthranilic acid (200 mg/kg, i.p., 6 weeks) contributes to angiotensin II–induced abdominal aortic aneurysm formation in mice[7].
3-hydroxyanthranilic acid (120 mg/kg, tail vein injection, once weekly, 12 weeks) combines with Butyricicoccus pullicaecorum to prevent postmenopausal osteoporosis in rats by modulating gut microbiota and Th17/Treg[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight

153.14

Formula

C7H7NO3
CAS No.
Appearance

Solid

Color

Light brown to light yellow

SMILES

O=C(O)C1=CC=CC(O)=C1N
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (326.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 6.5301 mL 32.6505 mL 65.3010 mL
5 mM 1.3060 mL 6.5301 mL 13.0602 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 2.5 mg/mL (16.33 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (16.33 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  50% PEG300    50% Saline

    Solubility: 20 mg/mL (130.60 mM); Suspended solution; Need ultrasonic

  • Protocol 2

    Add each solvent one by one:  0.5% CMC-Na/saline water

    Solubility: 20 mg/mL (130.60 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.73%

SDS (557 KB)

COA (247 KB) RP-HPLC (242 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 6.5301 mL 32.6505 mL 65.3010 mL 163.2525 mL
5 mM 1.3060 mL 6.5301 mL 13.0602 mL 32.6505 mL
10 mM 0.6530 mL 3.2651 mL 6.5301 mL 16.3253 mL
15 mM 0.4353 mL 2.1767 mL 4.3534 mL 10.8835 mL
20 mM 0.3265 mL 1.6325 mL 3.2651 mL 8.1626 mL
25 mM 0.2612 mL 1.3060 mL 2.6120 mL 6.5301 mL
30 mM 0.2177 mL 1.0884 mL 2.1767 mL 5.4418 mL
40 mM 0.1633 mL 0.8163 mL 1.6325 mL 4.0813 mL
50 mM 0.1306 mL 0.6530 mL 1.3060 mL 3.2651 mL
60 mM 0.1088 mL 0.5442 mL 1.0884 mL 2.7209 mL
80 mM 0.0816 mL 0.4081 mL 0.8163 mL 2.0407 mL
100 mM 0.0653 mL 0.3265 mL 0.6530 mL 1.6325 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

3-Hydroxyanthranilic acid Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

3-Hydroxyanthranilic acid548-93-6Endogenous Metabolitekynurenine pathwayT cellAnti-inflammatoryNeuroprotectiveCardiovascular diseasesTumorsand Metabolic diseases.Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
3-Hydroxyanthranilic acid
Cat. No.:
HY-W001171
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (557 KB) Français - FR (557 KB) Deutsch - DE (557 KB) Norwegian - NO (557 KB) Español - ES (557 KB) Swedish - SV (557 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.